Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 458104, 7 pages
http://dx.doi.org/10.1155/2014/458104
Research Article

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin

1Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, 1277 Jiefang Avenue, Wuhan 430022, China
2Department of Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, 1095 Jiefang Avenue, Wuhan 430030, China

Received 18 May 2014; Revised 14 July 2014; Accepted 28 July 2014; Published 14 August 2014

Academic Editor: Konstantinos Kantartzis

Copyright © 2014 Mohammad Ishraq Zafar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Xu, L. Wang, J. He et al., “Prevalence and control of diabetes in Chinese adults,” Journal of the American Medical Association, vol. 310, no. 9, pp. 948–958, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Q. Purnell, B. Zinman, J. D. Brunzell, P. A. Cleary, D. M. Nathan, and J. M. Lachin, “The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study,” Circulation, vol. 127, no. 2, pp. 180–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Banerji, M. A. Baron, L. Gao, and L. Blonde, “Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents,” Postgraduate Medicine, vol. 126, no. 3, pp. 111–125, 2014. View at Publisher · View at Google Scholar
  5. U. Pedersen-Bjergaard, P. L. Kristensen, and H. Beck-Nielsen, “Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial,” The Lancet Diabetes & Endocrinology, vol. 2, no. 7, pp. 553–561, 2014. View at Publisher · View at Google Scholar
  6. G. Koehler, G. Treiber, A. Wutte et al., “Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single doses and under steady-state conditions in patients with type 1 diabetes,” Diabetes, Obesity and Metabolism, vol. 16, no. 1, pp. 57–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Hod, E. R. Mathiesen, L. Jovanovič et al., “A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 27, no. 1, pp. 7–13, 2014. View at Publisher · View at Google Scholar
  8. J. G. Smith, T. A. Manuck, J. White, and D. C. Merrill, “Insulin glargine versus neutral protamine hagedorn insulin for treatment of diabetes in pregnancy,” American Journal of Perinatology, vol. 26, no. 1, pp. 57–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, “A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes,” Diabetologia, vol. 51, no. 3, pp. 408–416, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. S. Egerman, R. D. Ramsey, L. W. Kao et al., “Perinatal outcomes in pregnancies managed with antenatal insulin glargine,” The American Journal of Perinatology, vol. 26, no. 8, pp. 591–595, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. G. Swinnen, A. C. Simon, F. Holleman, J. B. Hoekstra, and J. H. Devries, “Insulin detemir versus insulin glargine for type 2 diabetes mellitus.,” Cochrane Database of Systematic Reviews, no. 7, 2011. View at Google Scholar · View at Scopus
  12. O. Klein, J. Lynge, L. Endahl, B. Damholt, L. Nosek, and T. Heise, “Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 290–299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Hallschmid, K. Jauch-Chara, O. Korn et al., “Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects,” Diabetes, vol. 59, no. 4, pp. 1101–1107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Sahu, “Leptin decreases food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat,” Endocrinology, vol. 139, no. 11, pp. 4739–4742, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Tatemoto and Y. Neuropeptide, History and Overview, Handbook of Experimental Pharmacology, vol. 162, Springer, Berlin, Germany, 2004.
  16. P. Fang, M. Yu, L. Guo, P. Bo, Z. Zhang, and M. Shi, “Galanin and its receptors: a novel strategy for appetite control and obesity therapy,” Peptides, vol. 36, no. 2, pp. 331–339, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. A. O. Schaffhauser, A. Stricker-Krongrad, L. Brunner et al., “Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides,” Diabetes, vol. 46, no. 11, pp. 1792–1798, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. M. S. Winzell and B. Ahrén, “The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes,” Diabetes, vol. 53, supplement 3, pp. S215–S219, 2004. View at Google Scholar
  19. K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, “Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening,” Pharmacological Research, vol. 52, no. 4, pp. 313–320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Hollander, J. Cooper, J. Bregnhøj, and C. B. Pedersen, “A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes,” Clinical Therapeutics, vol. 30, no. 11, pp. 1976–1987, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Sobrino Crespo, A. Perianes Cachero, L. Puebla Jiménez, V. Barrios, and E. Arilla Ferreiro, “Peptides and food intake,” Frontiers in Endocrinology, vol. 5, article 58, 2014. View at Publisher · View at Google Scholar
  22. D. K. Sindelar, P. Mystkowski, D. J. Marsh, R. D. Palmiter, and M. W. Schwartz, “Attenuation of diabetic hyperphagia in neuropeptide Y-deficient mice,” Diabetes, vol. 51, no. 3, pp. 778–783, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Mitsukawa, X. Lu, and T. Bartfai, “Galanin, galanin receptors, and drug targets.,” EXS, vol. 102, pp. 7–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Wang and K. L. Leibowitz, “Central insulin inhibits hypothalamic galanin and neuropeptide Y gene expression and peptide release in intact rats,” Brain Research, vol. 777, no. 1-2, pp. 231–236, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. P. A. Hollander, “Insulin detemir for the treatment of obese patients with type 2 diabetes,” Diabetes, Metabolic Syndrome and Obesity, vol. 5, pp. 11–19, 2012. View at Google Scholar
  26. A. M. Hennige, T. Sartorius, O. Tschritter et al., “Tissue selectivity of insulin detemir action in vivo,” Diabetologia, vol. 49, no. 6, pp. 1274–1282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. N. Singh, P. Vats, R. Shyam et al., “Role of neuropeptide Y and galanin in high altitude induced anorexia in rats,” Nutritional Neuroscience, vol. 4, no. 4, pp. 323–331, 2001. View at Google Scholar · View at Scopus